Trial · NCT07520110
Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis
NCT07520110, Phase 3, Not yet recruiting, University of Massachusetts, Worcester
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis. Trials, record NCT07520110. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07520110
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis
- NCT number
- NCT07520110
- Status
- Not yet recruiting
- Phases
- Phase 3
- Enrollment
- 800 participants, estimated
- Lead sponsor
- University of Massachusetts, Worcester
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Metformin, Matching Placebo
- First posted
- 2026-04-09
- Last updated
- 2026-09-08
Source ClinicalTrials.gov
Registered outcomes22
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Time to death, non-elective hospitalization, or lung transplantation | Baseline (visit 1) to up to 24 months | Clinical composite measure defined as the time from randomization to the first occurrence of any of its three components: all-cause mortality, first unplanned (non-elective) hospitalization, or lung transplantation. |
| Secondary | Time to all-cause mortality | Baseline (visit 1) to up to 24 months | The time from randomization to death from any cause. |
| Secondary | Time to first non-elective hospitalization | Baseline (visit 1) to up to 24 months | The time from randomization to the first unplanned inpatient hospital admission |
| Secondary | Time to lung transplantation | Baseline (visit 1) to up to 24 months | The time from randomization to the date of a participant's lung transplant |
| Secondary | Time to respiratory hospitalization | Baseline (visit 1) to up to 24 months | The time from randomization to the first non-elective respiratory hospitalization. Non-elective respiratory hospitalizations specifically refer to unplanned admissions where the primary cause is a pulmonary condition, as determined by a blinded adjudication committee. |
| Secondary | Change in Forced Vital Capacity (FVC) | Baseline (visit 1) to 12 months | The longitudinal change in forced vital capacity (measured in liters) based on spirometry from baseline (visit 1) to 12 months. |
| Secondary | Change in Forced Vital Capacity (FVC) % Predicted | Baseline (visit 1) to 12 months | The longitudinal change in FVC% predicted based on spirometry from baseline (visit 1) to 12 months. |
| Secondary | Change in Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO) corrected for hemoglobin. | Baseline (visit 1) to 12 months. | Units - ml/(min\*mmHg) |
| Secondary | Change in Six-Minute Walk Distance (6MWD) | Baseline (visit 1) to 12 months | The longitudinal change in the maximum distance (in meters) a participant can walk on a flat surface in six minutes. |
| Secondary | Change in patient reported outcomes scores for the Living with Pulmonary Fibrosis (L-PF) Impacts Questionnaire | Baseline (visit 1) to 12 months | The L-PF Impacts module contains 21 items (5-point Likert scale) that assesses the impact of disease on patients with pulmonary fibrosis. The range of the total score is 0-100, with higher scores indicating greater symptom severity. |
1 to 10 of 22Source ClinicalTrials.gov
See all 22 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07520110
GET https://conductscience.org/api/trials/v1/NCT07520110/registered?page=2